Loading...

CorMedix

DB:19KA
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
19KA
DB
$168M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • CorMedix has significant price volatility in the past 3 months.
19KA Share Price and Events
7 Day Returns
-3%
DB:19KA
-2.6%
DE Pharmaceuticals
-0.2%
DE Market
1 Year Returns
771.7%
DB:19KA
-28.9%
DE Pharmaceuticals
-10.3%
DE Market
19KA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CorMedix (19KA) -3% -15% -22.1% 771.7% -50.4% -
DE Pharmaceuticals -2.6% -4.6% -10.2% -28.9% -20.1% 5.5%
DE Market -0.2% -2.4% 4% -10.3% 11.2% 10.8%
1 Year Return vs Industry and Market
  • 19KA outperformed the Pharmaceuticals industry which returned -28.9% over the past year.
  • 19KA outperformed the Market in Germany which returned -10.3% over the past year.
Price Volatility
19KA
Industry
5yr Volatility vs Market

19KA Value

 Is CorMedix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CorMedix. This is due to cash flow or dividend data being unavailable. The share price is €6.233.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CorMedix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CorMedix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:19KA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.10
AMEX:CRMD Share Price ** AMEX (2019-05-20) in USD $7.07
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.4x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CorMedix.

DB:19KA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:CRMD Share Price ÷ EPS (both in USD)

= 7.07 ÷ -1.10

-6.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CorMedix is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • CorMedix is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CorMedix's expected growth come at a high price?
Raw Data
DB:19KA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-54.9%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.93x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CorMedix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CorMedix's assets?
Raw Data
DB:19KA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.69
AMEX:CRMD Share Price * AMEX (2019-05-20) in USD $7.07
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.3x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:19KA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:CRMD Share Price ÷ Book Value per Share (both in USD)

= 7.07 ÷ 0.69

10.18x

* Primary Listing of CorMedix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CorMedix is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess CorMedix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. CorMedix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

19KA Future Performance

 How is CorMedix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-54.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CorMedix expected to grow at an attractive rate?
  • Unable to compare CorMedix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CorMedix's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CorMedix's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:19KA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:19KA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -54.9%
DB:19KA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 61.2%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:19KA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:19KA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 122 1
2022-12-31 82 1
2021-12-31 47 1
2020-12-31 13 -50 2
2019-12-31 0 -24 1
DB:19KA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -24 -22
2018-12-31 0 -24 -27
2018-09-30 0 -24 -39
2018-06-30 0 -25 -39
2018-03-31 0 -29 -36
2017-12-31 0 -29 -33
2017-09-30 0 -28 -29
2017-06-30 0 -28 -28
2017-03-31 0 -24 -28
2016-12-31 0 -22 -25
2016-09-30 0 -19 -22
2016-06-30 0 -16 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CorMedix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CorMedix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:19KA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from CorMedix Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19KA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -1.63 -1.00 -2.26 2.00
2019-12-31 -0.98 -0.98 -0.98 1.00
DB:19KA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.10
2018-12-31 -1.51
2018-09-30 -2.47
2018-06-30 -2.74
2018-03-31 -2.79
2017-12-31 -2.99
2017-09-30 -3.00
2017-06-30 -3.27
2017-03-31 -3.59
2016-12-31 -3.25
2016-09-30 -3.02
2016-06-30 -2.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CorMedix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CorMedix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CorMedix has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

19KA Past Performance

  How has CorMedix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CorMedix's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CorMedix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CorMedix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CorMedix's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
CorMedix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CorMedix Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:19KA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.57 -21.81 8.16 13.42
2018-12-31 0.43 -26.83 8.07 18.82
2018-09-30 0.50 -39.29 7.83 31.63
2018-06-30 0.18 -39.01 7.81 29.35
2018-03-31 0.31 -35.60 7.91 27.84
2017-12-31 0.33 -33.01 8.65 24.49
2017-09-30 0.36 -29.10 9.12 20.06
2017-06-30 0.34 -28.27 9.44 20.89
2017-03-31 0.22 -28.12 9.47 18.57
2016-12-31 0.22 -24.64 8.88 15.74
2016-09-30 0.13 -22.11 8.72 13.19
2016-06-30 0.12 -17.67 9.35 8.11
2016-03-31 0.22 -16.81 9.62 7.14
2015-12-31 0.21 -18.22 10.26 6.28
2015-09-30 0.27 -16.57 9.52 5.30
2015-06-30 0.29 -16.94 8.16 3.83
2015-03-31 0.21 -9.33 7.51 2.20
2014-12-31 0.19 -20.54 7.33 1.32
2014-09-30 0.11 -21.78 7.33 0.66
2014-06-30 0.05 -19.27 6.24 1.12
2014-03-31 0.01 -24.70 5.45 1.32
2013-12-31 0.00 -9.52 3.49 1.23
2013-09-30 -6.91 2.16 1.68
2013-06-30 -5.38 2.40 1.18
2013-03-31 -4.04 1.87 1.03
2012-12-31 -3.38 1.86 1.14
2012-09-30 -2.15 2.20 0.42
2012-06-30 -3.73 2.33 1.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CorMedix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CorMedix has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CorMedix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CorMedix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CorMedix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

19KA Health

 How is CorMedix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CorMedix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CorMedix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CorMedix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CorMedix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CorMedix Company Filings, last reported 1 month ago.

DB:19KA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 16.54 6.43 26.20
2018-12-31 4.93 6.13 17.62
2018-09-30 -9.50 0.00 6.44
2018-06-30 -6.48 0.00 4.70
2018-03-31 0.84 0.00 8.16
2017-12-31 7.19 0.00 11.98
2017-09-30 9.68 0.00 12.01
2017-06-30 15.37 0.00 18.82
2017-03-31 11.04 0.00 13.77
2016-12-31 17.81 0.00 20.17
2016-09-30 23.78 0.00 26.65
2016-06-30 28.07 0.00 28.61
2016-03-31 30.52 0.00 30.23
2015-12-31 34.01 0.00 35.39
2015-09-30 36.39 0.00 37.85
2015-06-30 36.85 0.00 37.49
2015-03-31 7.60 0.00 8.80
2014-12-31 3.63 0.00 4.34
2014-09-30 5.58 0.00 5.92
2014-06-30 4.81 0.00 7.65
2014-03-31 6.51 0.00 9.19
2013-12-31 0.63 0.00 2.37
2013-09-30 -2.74 1.53 0.48
2013-06-30 -2.03 0.70 0.16
2013-03-31 -1.13 0.60 0.69
2012-12-31 -0.34 0.27 0.84
2012-09-30 -0.44 0.17 0.99
2012-06-30 -0.14 0.00 0.89
  • CorMedix's level of debt (38.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 38.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CorMedix has sufficient cash runway for 1.1 years based on current free cash flow.
  • CorMedix has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 12.1% each year.
X
Financial health checks
We assess CorMedix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CorMedix has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

19KA Dividends

 What is CorMedix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CorMedix dividends.
If you bought €2,000 of CorMedix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CorMedix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CorMedix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:19KA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:19KA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CorMedix has not reported any payouts.
  • Unable to verify if CorMedix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CorMedix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CorMedix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CorMedix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CorMedix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CorMedix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

19KA Management

 What is the CEO of CorMedix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Khoso Baluch
COMPENSATION $586,841
AGE 60
TENURE AS CEO 2.6 years
CEO Bio

Mr. Khoso Baluch has been the Chief Executive Officer of CorMedix, Inc. since October 3, 2016. Mr. Baluch served as Senior Vice President and President Europe, Middle East & Africa EMEA at UCB, SA or UCB, from January 2015 to early 2016, Senior Vice President and President of the European Region of UCB from February 2013 to December 2014 and Senior Vice President and Chief Marketing Officer of UCB from January 2010 to February 2013. Prior to joining UCB, Mr. Baluch worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. He has been a Director of CorMedix, Inc. since October 3, 2016. He has served as an Independent Director of Poxel SA, a French publically traded biotech company, since 2013. Mr. Baluch holds a BSc in Aeronautical Engineering from City University London and a Masters of Business Administration from Cranfield School of Management.

CEO Compensation
  • Khoso's compensation has increased whilst company is loss making.
  • Khoso's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CorMedix management team in years:

2.2
Average Tenure
61
Average Age
  • The tenure for the CorMedix management team is about average.
Management Team

Khoso Baluch

TITLE
CEO & Director
COMPENSATION
$587K
AGE
60
TENURE
2.6 yrs

Bob Cook

TITLE
Chief Financial Officer
COMPENSATION
$434K
AGE
62
TENURE
2.3 yrs

Jack Armstrong

TITLE
Head of Human Resources & Executive VP of Technical Operations
COMPENSATION
$369K
AGE
74
TENURE
2.2 yrs

Liz Masson

TITLE
Executive VP & Head of Clinical Operations
COMPENSATION
$364K
AGE
39
TENURE
1.2 yrs

Phoebe Mounts

TITLE
Executive VP & General Counsel

Paul Chew

TITLE
Consultant Advisor Chief Medical Officer
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the CorMedix board of directors in years:

1.9
Average Tenure
61
Average Age
  • The average tenure for the CorMedix board of directors is less than 3 years, this suggests a new board.
Board of Directors

Myron Kaplan

TITLE
Chairman of the Board
COMPENSATION
$71K
AGE
72
TENURE
1.8 yrs

Khoso Baluch

TITLE
CEO & Director
COMPENSATION
$587K
AGE
60
TENURE
2.6 yrs

Steve Lefkowitz

TITLE
Director
COMPENSATION
$67K
AGE
62
TENURE
1.9 yrs

Michael Allon

TITLE
Chairman of Scientific Advisor Board

Janet Dillione

TITLE
Independent Director
COMPENSATION
$54K
AGE
59
TENURE
3.8 yrs

Mehmood Khan

TITLE
Director
COMPENSATION
$54K
AGE
59
TENURE
1.9 yrs

Paul Flyer

TITLE
Member of Scientific Advisor Board

Bruce Reidenberg

TITLE
Member of Scientific Advisor Board

C. Webb

TITLE
Member of Scientific Advisor Board

Bruce Polsky

TITLE
Member of Scientific Advisor Board
AGE
64
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by CorMedix insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. May 19 Buy Janet Dillione Individual 15. May 19 15. May 19 11,144 €6.02 €67,044
01. Apr 19 Buy Robert Cook Individual 29. Mar 19 29. Mar 19 100 €8.33 €833
27. Mar 19 Buy John Armstrong Individual 26. Mar 19 26. Mar 19 5,000 €6.85 €34,240
27. Mar 19 Buy Khoso Baluch Individual 26. Mar 19 26. Mar 19 2,500 €6.69 €16,721
25. Mar 19 Buy John Armstrong Individual 25. Mar 19 25. Mar 19 3,000 €7.47 €22,407
22. Mar 19 Buy Myron Kaplan Individual 22. Mar 19 22. Mar 19 4,000 €7.30 €29,218
20. Mar 19 Buy Janet Dillione Individual 18. Mar 19 18. Mar 19 8,400 €7.35 €61,729
21. Dec 18 Buy Mehmood Khan Individual 20. Dec 18 20. Dec 18 20,000 €5.45 €108,971
21. Dec 18 Buy Wade Capital Corporation, Money Purchase Plan Company 20. Dec 18 20. Dec 18 4,000 €5.15 €20,584
17. Dec 18 Buy Myron Kaplan Individual 14. Dec 18 14. Dec 18 10,000 €6.49 €64,900
30. Nov 18 Buy John Armstrong Individual 29. Nov 18 29. Nov 18 50,000 €6.38 €319,136
27. Nov 18 Buy Khoso Baluch Individual 26. Nov 18 27. Nov 18 5,000 €5.67 €27,003
27. Nov 18 Buy Myron Kaplan Individual 23. Nov 18 23. Nov 18 10,000 €5.72 €57,156
27. Nov 18 Buy Robert Cook Individual 27. Nov 18 27. Nov 18 5,000 €5.17 €25,868
X
Management checks
We assess CorMedix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CorMedix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

19KA News

Simply Wall St News

19KA Company Info

Description

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Details
Name: CorMedix, Inc.
19KA
Exchange: DB
Founded: 2006
$150,566,971
23,792,427
Website: http://www.cormedix.com
Address: CorMedix, Inc.
400 Connell Drive,
Suite 5000,
Berkeley Heights,
New Jersey, 07922,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX CRMD Class A Common Stock NYSE MKT LLC US USD 13. May 2010
DB 19KA Class A Common Stock Deutsche Boerse AG DE EUR 13. May 2010
Number of employees
Current staff
Staff numbers
22
CorMedix employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 22:33
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.